BioSpace News Archive

Vivani Medical, Inc. today announced the appointment of long-time industry veteran Daniel Bradbury to its Board of Directors.

Coya Therapeutics, Inc. announces the presentation of data demonstrating the role of the peripheral immune system in the pathophysiology of Frontotemporal Dementia (FTD) from a biomarker study conducted at the Houston Methodist Hospital by Dr. Stanley Appel and Dr. Alireza Faridar and funded by the Houston Methodist Clinical Scholar Award Program.

Elicio Therapeutics, Inc. today announced three upcoming poster presentations at the American Association for Cancer Research (“AACR”) Annual Meeting taking place from April 5-10, 2024, in San Diego, California.

U.S. FDA accepted BLA for afami-cel for the treatment of advanced synovial sarcoma with priority review and a PDUFA date of August 4th, 2024

CorMedix Inc. today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2023, before the market opens on Tuesday, March 12, 2024, and will host a corporate update conference call at 8:30am Eastern Time.

Capricor Therapeutics announced today that the Company will present the positive 24-month results from its HOPE-2 open-label extension (OLE) study with lead asset, CAP-1002, for the treatment of Duchenne muscular dystrophy (DMD).

Sofwave Medical Ltd (TASE: SOFW), an emerging leader in energy-based non-invasive, aesthetic medical devices for practitioners worldwide, reported financial results for the fourth quarter and full fiscal 2023 reporting period, for the period ended December 31, 2023, and recent business highlights.

MAIA Biotechnology, Inc. today announced positive efficacy data for third-line treatment in its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in advanced non-small cell lung cancer (NSCLC).

ResMed announced the U.S. launch of the AirFit F40, an ultra-compact, full-face mask offering the comfort of smaller masks without sacrificing performance in order to help improve sleep apnea therapy compliance.

CSL Seqirus, a global leader in the protection of public health, confirmed it is fully prepared to deliver its influenza vaccine portfolio for the 2024/25 U.S. season, based on the trivalent strains recommended this week by the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee.